Posted by Michael Wonder on 03 Aug 2024
FDA approves additional indication for Fibryga for fibrinogen supplementation in bleeding patients with acquired fibrinogen deficiency, potentially ushering in a new standard of care
1 August 2024 - Octapharma has announced the expanded approval of fibryga, fibrinogen (human) lyophilised powder for Reconstitution, for fibrinogen replacement in bleeding patients with acquired fibrinogen deficiency by the US FDA.
As the first and only on-demand, virus-inactivated, human plasma-derived fibrinogen concentrate option with this approval, fibryga represents a rapid and more precise option for severe bleeding scenarios than the current standard of care (cryoprecipitate).
